Bone drug may stop Paget's before it starts in at-risk families
NCT ID NCT03859895
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study follows people who carry a gene mutation that puts them at high risk for Paget's disease of the bone. They previously received either zoledronic acid or a placebo in the ZiPP trial. Now researchers will track them for another 5 years to see if the drug can prevent or delay bone lesions and symptoms. The goal is to learn whether early treatment can stop the disease from ever causing problems.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
zoledronic acid (a bisphosphonate drug)
What this could lead to
If it works, this could point toward a way to prevent Paget's disease in people who carry the high-risk gene mutation.
What could go wrong
This is an extension of an earlier trial, and it is still unclear whether preventing bone lesions will actually prevent symptoms. The study is small and focused on a specific genetic group, so results may not apply to everyone.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for PAGET DISEASE are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Guy's and St Thomas Hospital NHS Trust
London, England, SE1 9RT, United Kingdom
-
King's College Hospital
London, England, SE5 9RS, United Kingdom
-
Manchester Royal Infirmary
Manchester, England, M13 9WL, United Kingdom
-
NHS Lothian
Edinburgh, Scotland, EH4 2XU, United Kingdom
-
Royal Newcastle Centre
Newcastle, NSW 2305, Australia
-
Sir Charles Gardner Hospital
Nedlands, 6009, Australia
-
St. Vincent's University Hospital
Dublin, Ireland
-
The Princess Margaret Hospital
Christchurch, 731 8022, New Zealand
-
Univeristy of Barcelona
Barcelona, Spain
-
University Hospital Geelong
Geelong, 3220, Australia
-
University Hospital Saint-Luc
Brussels, Belgium
-
University Hospital of Careggi
Florence, 50139, Italy
-
University Hospital of Salamanca
Salamanca, 37007, Spain
-
University of Auckland
Auckland, 92019, New Zealand
-
University of Bristol
Bristol, England, BC10 5NB, United Kingdom
-
University of Liverpool
Liverpool, England, L7 8XP, United Kingdom
-
University of Queensland
Toowoomba, QLD 4350, Australia
-
University of Siena
Siena, 53100, Italy
-
University of Sydney
Sydney, Australia
-
University of Turin
Turin, 10126, Italy
-
Wrexham Maelor Hospital
Wrexham, Wales, LL13 7TD, United Kingdom